Mechanisms of diabetic vasculopathy: An overview

American Journal of Hypertension

Volumn 14, Issue 5 I, 2001, Pages 475-486

  Cooper, Mark E ^a   Bonnet, Fabrice ^a   Oldfield, Matthew ^a   Jandeleit Dahm, Karin ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin; Diabetes; Endothelin; Glycation; Growth factors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOKINE; GLUCOSE; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; HEMODYNAMICS; HUMAN; HYPERTENSION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS; HUMANS; MESENTERIC ARTERIES; SPLANCHNIC CIRCULATION; VASCULAR DISEASES;

EID: 0035021995     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(00)01323-6     Document Type: Review

References (149)

1. Optimizing treatment of hypertension in patients with diabetes
2. Vascular dysfunction in diabetes mellitus
3. Prevention and treatment of the complications of diabetes mellitus
4. Pathophysiology of diabetic nephropathy
5. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition
6. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products
7. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism
8. Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks
9. Cellular mechanisms of diabetic vascular hypertrophy
10. The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery
11. Pathogenesis, prevention and treatment of diabetic nephropathy
12. Systemic hypertension and the reninangiotensin system in diabetic vascular complications
13. Signal transduction of mechanical stresses in the vascular wall
14. Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow
15. Flow-induced arterial remodeling in rat mesenteric vasculature
16. Pressure and angiotensin II synergistically induce aortic fibronectin expression in organ culture model of rabbit aorta. Evidence for a pressure-induced tissue renin-angiotensin system
17. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro
18. Transforming growth factor-beta in tissue fibrosis
19. Diabetes mellitus and vascular lesions
20. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
21. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
22. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus
24. Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action
25. Kinins/nitric oxide are involved in the anti-trophic effects of ACE inhibitors on diabetes associated mesenteric vascular hypertrophy
26. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta(1) and type IV collagen in diabetic vasculopathy
27. Vasular smooth muscle cell hypertrophy vs hyperplasia: Autocrine transforming growth factorbeta 1 expression determines growth response to angiotensin II
28. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells
29. The role of angiotensin II in vascular smooth muscle cell growth
30. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy
31. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
32. Renal circulation and blockade of the renin angiotensin system. Is angiotensin-converting enzyme inhibition the last word?
33. Characterisation of angiotensin converting enzyme from different rat vascular beds
34. Role for NADPH/NADH oxidase in the modulation of vascular tone
35. Endothelial dysfunction in diabetes mellitus
36. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
37. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus
38. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study
39. Conversion of angiotensin I to angiotensin II
40. Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes
41. Is there a role for endothelin antagonists in diabetic renal diseases?
42. Influence of noninsulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis
43. ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits
44. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
45. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats
46. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes
47. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
48. The renin-angiotensin system in diabetic nephropathy: The endothelial connection
49. Selective impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated resistance arteries of the streptozotocin-induced diabetic rat
50. Augmented thromboxane generation by mesenteric arteries from pancreatectomized diabetic dogs is coincident with the vascular tone enhancement evoked by Na arachidonate and prostacyclin
51. Role of extracellular Ca2+ in the selective enhancement of contractile responses of arteries from diabetic rats to noradrenaline
52. Vascular contraction induced by activation of membrane calcium ion channels is enhanced in streptozotocin-diabetes
53. Protein kinase C-mediated contractile responses of arteries from diabetic rats
54. Augmented inositol phosphate production in mesenteric arteries from diabetic rats
55. Modification of vasodilator response in streptozotocin-induced diabetic rat
56. Fosinopril improves regulation of vascular tone in mesenteric bed of diabetic rats
57. Changes in endothelium-dependent relaxation and levels of cyclic nucleotides in the perfused mesenteric arterial bed from streptozotocin-induced diabetic rats
58. Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats
59. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: Role of free radicals
60. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels
61. Vascular reactivity to noradrenaline and neuropeptide Y in the streptozotocin-induced diabetic rat
62. Vascular reactivity
63. Hyperglycemia and cardiovascular disease in type 2 diabetes
64. Hypertension and macrovascular disease - The killing fields of NIDDM
65. The cellular and molecular mechanisms of diabetic complications
66. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: Morphological and molecular biological studies
67. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
68. Nonenzymatic glycosylation and the pathogenesis of diabetic complications
69. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
70. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
71. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes
72. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
73. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor
74. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
75. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
76. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat
77. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
78. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat
79. The dark side of glucose
80. Accumulation of Maillard reaction products in skin collagen in diabetes and aging
81. Action des acides amines sur les sucres; formation des melanoides par voie methodique
82. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction
83. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo
84. The advanced glycation end product, Nepsilon-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions
85. Glucose autoxidation and protein modification. The potential role of "autoxidative glycosylation" in diabetes
86. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
87. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins
88. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex
89. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction
90. RAGE: A novel cellular receptor for advanced glycation end products
91. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
92. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
93. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
94. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
95. Nonenzymatic glucosylation and glucose-dependent cross-linking of protein
96. Structure elucidation of a senescence crosslink from human extracellular matrix. Implication of pentoses in the aging process
97. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice
98. Advanced protein glycosylation in diabetes and aging
99. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits
100. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging
101. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
102. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
103. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
104. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit
105. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility
106. Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells
107. PDGF and TGF-beta mediate collagen production by mesangial cells ex posed to advanced glycation end product
108. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
109. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
110. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
111. Amino-guanidine prevents diabetes-induced arterial wail protein crosslinking
112. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis
113. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
114. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
115. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
116. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness
117. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
118. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
119. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy
120. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart
121. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C
122. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: Prevention by calphostin C
123. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells
124. Effects of polyolpathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats
125. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: Effect of treatment with the aldose reductase inhibitor, ponalrestat
126. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
127. Inhibition of platelet-derived growth factors receptor kinase inhibits smooth muscle cell migration and proliferation
128. Impaired nitric oxide-mediated vasodilation in patients with noninsulin-dependent diabetes mellitus
129. Nitric oxide in the juxtaglomerular apparatus
130. Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions
131. Factors regulating the expression of vascular permeability vascular endothelial growth factor by human vascular tissues
132. Advanced glycation end products increase retinal vascular endothelial growth factor expression
133. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
134. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
135. Upregulation of the vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat
136. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
137. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
138. Further studies on the delayed mast-cell-mediated mitogenesis in diabetic rat
139. Acute hyperglycaemia and mast-cell-dependent mitogenesis in rat
140. Increased angiogenesis in diabetes
141. Increased production of PDGF by angiotensin and high glucose in human vascular endothelium
142. Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy
143. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix
144. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway
145. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors
146. Induction of TGF-betal by the matricellular protein SPARC in a rat model of glomerulonephritis
147. Distribution of SPARC in normal and neoplastic human tissue
148. SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy
149. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1